Business, energy, technology, markets and global industry news from Business News Today

Glaukos Corporation

PharmaDeviceNews Glaukos Corporation
An ophthalmic surgeon performs a glaucoma procedure as Glaukos Corporation advances the PRESERFLO MicroShunt through its U.S. pivotal study following completion of patient enrollment. Representative image.
Medical Devices & Diagnostics

Glaukos has enrolled the PRESERFLO pivotal study, but the decisive U.S. evidence is still ahead

Glaukos completes PRESERFLO pivotal enrollment, shifting focus to 12-month data, FDA clearance and advanced glaucoma adoption.

Read More
Representative image: An ophthalmic examination highlights the clinical focus of Glaukos Corporation’s GLK-321 Phase 2 study, which is evaluating a dropless eyelid-applied treatment for Demodex blepharitis.
Pharma & Biotech

Glaukos completes enrollment in GLK-321 trial as Demodex therapy competition grows

Discover how Glaukos’ GLK-321 Phase 2 trial could reshape Demodex blepharitis care through a dropless eyelid-applied treatment.

Read More
Pharma & Biotech

What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement

Glaukos secures a permanent J-code for Epioxa. Read why this reimbursement milestone could shape keratoconus treatment adoption and payer access.

Read More
Medical Devices & Diagnostics

Is Glaukos building a multi-franchise ophthalmology platform through Epioxa and glaucoma implants?

Glaukos heads to ASCRS 2026 with Epioxa and glaucoma data. Read what this could change for keratoconus, sustained therapy, and adoption.

Read More